THO 0730 A Phase II Trial of Celecoxib Plus Chemotherapy (Docetaxel or Pemetrexed) in Patients with Previously Treated 'Cox Dependent' Recurrent Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Celecoxib (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms SPORE
- 07 Jun 2017 Biomarkers information updated
- 06 Feb 2013 Planned End Date changed from 1 Jan 2016 to 1 Dec 2019 as reported by ClinicalTrials.gov.
- 06 Feb 2013 New source identified and integrated (Vanderbilt University Institutional Review Board: 070723).